Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and γ-secretase. Also provided are methods of using the derivatives to treat pathological disorders.
1. A compound of the following formula:
wherein
R 1 is selected from the group consisting of hydrogen, halo, CF 3 ; SCH 3 ; SOCH 3 ; SO 2 CH 3 ; SO 2 NH 2 ; C 1 to C 6 alkyl, branched alkyl, or substituted alkyl; C 1 to C 6 alkoxy, branched alkoxy, or substituted alkoxy; C 1 to C 6 alkylcarboxyl ic acid, branched alkylcarboxylic acid, or substituted alkylcarboxylic acid; and CH 2 N 3 ;
R 2 is selected from the group consisting of hydrogen, halo, CF 3 ; SCH 3; SOCH 3 ; SO 2 CH 3 ; SO 2 NH 2 ; CONH 2 ; C 1 to C 6 alkyl, branched alkyl, or substituted alkyl; C 1 to C 6 alkoxy, branched alkoxy, or substituted alkoxy; benzyloxy; C 1 to C 6 alkylcarboxylic acid, branched alkylcarboxylic acid, or substituted alkylcarboxylic acid; and CH 2 N 3 ;
R 3 and R 4 are each independently selected from the group consisting of hydrogen; halo; CF 3 ; C 1 to C 6 alkyl, branched alkyl, or substituted alkyl; C 1 to C 6 alkoxy, branched alkoxy, or substituted alkoxy; aryl; substituted aryl; benzyloxy; SCH 3 ; SOCH 3 ; SO 2 CH 3 ; and SO 2 NH 2 ;
R 5 is selected from the group consisting of hydrogen, C 1 to C 6 alkyl, branched alkyl, or substituted alkyl, and ═O;
R* is selected from the group consisting of phenyl and singly or multiply substituted phenyl;
has the following structure:
Y is selected from the group consisting of hydrogen; halo; halomethyl, wherein at least one hydrogen of the methyl group is substituted with a halogen; C 2 to C 6 alkyl; C 2 to C 6 branched alkyl; and C 2 to C 6 substituted alkyl;
A is selected from the group consisting of carbon and nitrogen;
p and q are both individually 0, 1, 2, 3, or 4;
the bond between the carbon bound to R 5 and the indene ring and is a single bond or a double bond; and
the six-membered ring to which R 1 is bound is cyclohexyl or phenyl.
2. The compound of claim 1 , wherein
R 1 is selected from the group consisting of C 1 to C 6 alkylcarboxylic acid and branched C 1 to C 6 alkylcarboxylic acid;
R 2 is selected from the group consisting of halo, C 1 to C 6 alkyl or branched alkyl,
SCH 3 , SOCH 3 , SO 2 CH 3 , and SO 2 NH 2 ; and
R 3 —R 5 are each independently selected from the group consisting of hydrogen, C 1 to C 6 alkyl or branched alkyl, and halo.
3. The compound of claim 1 , wherein the compound has the following general formula:
4. The compound of claim 1 wherein R* is a singly or multiply substituted phenyl, and further wherein each substituent is selected from the group consisting of a halogen, NH 2 , OCH 3 , CF 3 , OH, C 1 to C 4 alkyl or branched alkyl, NO 2 , benzoyl, 2-phenyl-oxirane, and NH—CO—CH 2 Br.
5. The compound of claim 1 , wherein the compound has the following general formula:
wherein R 12 is selected from the group consisting of phenyl, phenyl-CH 3 , phenyl-COOH, phenyl-SCH 3 , phenyl-SOCH 3 , phenyl-SO 2 CH 3 , o-, m-, or p-halo-phenyl and combinations thereof, phenyl-CH 2 N 3 , and C 3 to C 6 cycloalkyl.
6. The compound of claim 1 , wherein the compound has the following general formula:
wherein R 11 is selected from the group consisting of
7. The compound of claim 1 , wherein the compound has the following structure: